Liuchun Wang

发表

Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer

Bao-cun Sun, Li Lin, Xi-yin Wei, 2012, Journal of Cancer Research and Clinical Oncology.

Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states

Bao-cun Sun, Li Lin, Chun Huang, 2011, Chinese medical journal.

Incidence and clinical implication of tumor cavitation in patients with advanced non‐small cell lung cancer induced by Endostar, an angiogenesis inhibitor

Li Lin, Jianyu Xiao, Xuan Wang, 2014, Thoracic cancer.

Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements

Fan Wang, Liuchun Wang, Xinyue Wang, 2019, Medical science monitor : international medical journal of experimental and clinical research.

Astragalus polysaccharide promotes the release of mature granulocytes through the L-selectin signaling pathway

Lei-ming Guo, Liuchun Wang, Ping-ping Zhang, 2015, Chinese Medicine.

XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.

Li Lin, T. Sun, Guang Yang, 2021, Cancer letters.

PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level

Liuchun Wang, Kai Li, Xinyue Wang, 2017, Journal of Cancer.

Circulating endothelial cells and tumor blood volume as predictors in lung cancer

Li Lin, Baocun Sun, Jianyu Xiao, 2013, Cancer science.

Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma

Lei-na Sun, Zi-liang Jin, Zhu-jun Liu, 2011, Molecular Diagnosis & Therapy.

A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors

Mei-Ching Liu, Zhongling Zhu, Chun Huang, 2011, Cancer Chemotherapy and Pharmacology.

Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma.

Lei-na Sun, Zi-liang Jin, Zhu-jun Liu, 2011, Molecular diagnosis & therapy.

The analysis of rubitecan in phase I tolerance trial

Li Lin, Chun Huang, Peng Chen, 2009 .

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

Li Lin, Xiaoling Zhang, Tingting Qin, 2018, Cancer medicine.

bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer

S. Chuai, Xiaojie Pan, S. Cai, 2023, EBioMedicine.

Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).

D. Zhong, Y. Shang, Dingzhi Huang, 2020 .

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

D. Zhong, Yan Zhang, Y. Shang, 2023, Molecular Cancer.